File Download
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1093/cid/ciy759
- Scopus: eid_2-s2.0-85064250892
- PMID: 30202873
- WOS: WOS:000482143600020
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: Influenza hemagglutination-inhibition antibody titer as a mediator of vaccine-induced protection for influenza B
Title | Influenza hemagglutination-inhibition antibody titer as a mediator of vaccine-induced protection for influenza B |
---|---|
Authors | |
Keywords | Influenza Vaccination Hemagglutination inhibition Correlate of protection |
Issue Date | 2019 |
Publisher | Oxford University Press. The Journal's web site is located at http://www.oxfordjournals.org/our_journals/cid/ |
Citation | Clinical Infectious Diseases, 2019, v. 68 n. 10, p. 1713-1717 How to Cite? |
Abstract | Background: The hemagglutination inhibition (HAI) assay is an established correlate of protection for the inactivated influenza vaccine. However, the proportion of vaccine-induced protection that is mediated by the post-vaccination HAI titer has not been assessed.
Methods: We used data from a randomized, placebo-controlled trial of a split-virion inactivated influenza vaccine in children aged 6–17 years. Sera were collected before and 30 days after receipt of vaccination or placebo and tested by the HAI assay against B/Brisbane/60/2008-like (B/Victoria lineage). We fitted Cox proportional hazards models to the time to laboratory-confirmed influenza B. We used causal mediation analysis to estimate the proportion of the total effect of vaccination that was mediated by higher HAI titers.
Results: We estimated that vaccine efficacy against confirmed B/Victoria infection was 68% (95% confidence interval, 33%, 88%), and post-vaccination HAI titers explained 57% of the effect of vaccination on protection.
Conclusions:
The majority of the effect of inactivated influenza vaccination in children is mediated by the increased HAI titer after vaccination; however, other components of the immune response to vaccination may also play a role in protection and should be further explored. Causal mediation analysis provides a framework to quantify the role of various mediators of protection. |
Persistent Identifier | http://hdl.handle.net/10722/262257 |
ISSN | 2023 Impact Factor: 8.2 2023 SCImago Journal Rankings: 3.308 |
ISI Accession Number ID |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Cowling, BJ | - |
dc.contributor.author | Lim, WW | - |
dc.contributor.author | Perera, RAPM | - |
dc.contributor.author | Fang, J | - |
dc.contributor.author | Leung, GM | - |
dc.contributor.author | Peiris, JSM | - |
dc.contributor.author | Tchetgen Tchetgen, EJ | - |
dc.date.accessioned | 2018-09-28T04:56:09Z | - |
dc.date.available | 2018-09-28T04:56:09Z | - |
dc.date.issued | 2019 | - |
dc.identifier.citation | Clinical Infectious Diseases, 2019, v. 68 n. 10, p. 1713-1717 | - |
dc.identifier.issn | 1058-4838 | - |
dc.identifier.uri | http://hdl.handle.net/10722/262257 | - |
dc.description.abstract | Background: The hemagglutination inhibition (HAI) assay is an established correlate of protection for the inactivated influenza vaccine. However, the proportion of vaccine-induced protection that is mediated by the post-vaccination HAI titer has not been assessed. Methods: We used data from a randomized, placebo-controlled trial of a split-virion inactivated influenza vaccine in children aged 6–17 years. Sera were collected before and 30 days after receipt of vaccination or placebo and tested by the HAI assay against B/Brisbane/60/2008-like (B/Victoria lineage). We fitted Cox proportional hazards models to the time to laboratory-confirmed influenza B. We used causal mediation analysis to estimate the proportion of the total effect of vaccination that was mediated by higher HAI titers. Results: We estimated that vaccine efficacy against confirmed B/Victoria infection was 68% (95% confidence interval, 33%, 88%), and post-vaccination HAI titers explained 57% of the effect of vaccination on protection. Conclusions: The majority of the effect of inactivated influenza vaccination in children is mediated by the increased HAI titer after vaccination; however, other components of the immune response to vaccination may also play a role in protection and should be further explored. Causal mediation analysis provides a framework to quantify the role of various mediators of protection. | - |
dc.language | eng | - |
dc.publisher | Oxford University Press. The Journal's web site is located at http://www.oxfordjournals.org/our_journals/cid/ | - |
dc.relation.ispartof | Clinical Infectious Diseases | - |
dc.rights | This is a pre-copy-editing, author-produced PDF of an article accepted for publication in Clinical Infectious Diseases following peer review. The definitive publisher-authenticated version Clinical Infectious Diseases, 2019, v. 68 n. 10, p. 1713-1717 is available online at: https://dx.doi.org/10.1093/cid/ciy759 | - |
dc.subject | Influenza | - |
dc.subject | Vaccination | - |
dc.subject | Hemagglutination inhibition | - |
dc.subject | Correlate of protection | - |
dc.title | Influenza hemagglutination-inhibition antibody titer as a mediator of vaccine-induced protection for influenza B | - |
dc.type | Article | - |
dc.identifier.email | Cowling, BJ: bcowling@hku.hk | - |
dc.identifier.email | Perera, RAPM: mahenp@hku.hk | - |
dc.identifier.email | Fang, J: vickyf@hku.hk | - |
dc.identifier.email | Leung, GM: gmleung@hku.hk | - |
dc.identifier.email | Peiris, JSM: malik@hkucc.hku.hk | - |
dc.identifier.authority | Cowling, BJ=rp01326 | - |
dc.identifier.authority | Perera, RAPM=rp02500 | - |
dc.identifier.authority | Leung, GM=rp00460 | - |
dc.identifier.authority | Peiris, JSM=rp00410 | - |
dc.description.nature | postprint | - |
dc.identifier.doi | 10.1093/cid/ciy759 | - |
dc.identifier.pmid | 30202873 | - |
dc.identifier.scopus | eid_2-s2.0-85064250892 | - |
dc.identifier.hkuros | 293276 | - |
dc.identifier.volume | 68 | - |
dc.identifier.issue | 10 | - |
dc.identifier.spage | 1713 | - |
dc.identifier.epage | 1717 | - |
dc.identifier.isi | WOS:000482143600020 | - |
dc.publisher.place | United States | - |
dc.identifier.issnl | 1058-4838 | - |